Research Article

Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma

Published: October 20, 2009
Genet. Mol. Res. 8 (4) : 1257-1263 DOI: https://doi.org/10.4238/vol8-4gmr631
Cite this Article:
N.P. Anselmo, J.A. Rey, L.O. Almeida, A.C. Custódio, J.R.W. Almeida, C.A. Clara, M.J. Santos, C. Casartelli (2009). Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma. Genet. Mol. Res. 8(4): 1257-1263. https://doi.org/10.4238/vol8-4gmr631
1,457 views

Abstract

Disruption or loss of tumor suppressor gene TP53 is implicated in the development or progression of almost all different types of human malignancies. Other members of the p53 family have been identified. One member, p73, not only shares a high degree of similarity with p53 in its primary sequence, but also has similar functions. Like p53, p73 can bind to DNA and activate transcription. Using PCR-SSCP and gene sequencing, we analyzed the TP53 and TP73 genes in a case of a grade III anaplastic astrocytoma that progressed to glioblastoma. We found a deletion of AAG at position 595-597 of TP53 (exon 6), resulting in the deletion of Glu 199 in the protein and a genomic polymorphism of TP73, identified as an A-to-G change, at position E8/+15 at intron 8 (IVS8-15A>G). The mutation found at exon 6 of the gene TP53 could be associated with the rapid tumoral progression found in this case, since the mutated p53 may inactivate the wild-type p53 and the p73a protein, which was conserved here, leading to an increase in cellular instability.

Disruption or loss of tumor suppressor gene TP53 is implicated in the development or progression of almost all different types of human malignancies. Other members of the p53 family have been identified. One member, p73, not only shares a high degree of similarity with p53 in its primary sequence, but also has similar functions. Like p53, p73 can bind to DNA and activate transcription. Using PCR-SSCP and gene sequencing, we analyzed the TP53 and TP73 genes in a case of a grade III anaplastic astrocytoma that progressed to glioblastoma. We found a deletion of AAG at position 595-597 of TP53 (exon 6), resulting in the deletion of Glu 199 in the protein and a genomic polymorphism of TP73, identified as an A-to-G change, at position E8/+15 at intron 8 (IVS8-15A>G). The mutation found at exon 6 of the gene TP53 could be associated with the rapid tumoral progression found in this case, since the mutated p53 may inactivate the wild-type p53 and the p73a protein, which was conserved here, leading to an increase in cellular instability.